The news of Cantor Fitzgerald reiterating a Neutral rating and maintaining a $200 price target on Alnylam Pharmaceuticals is directly related to the company. However, as it is a reiteration of the existing rating and price target, it is not expected to have a significant short-term impact on the stock price.